<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD1F1403-9928-4563-8E48-326ACF87C706"><gtr:id>DD1F1403-9928-4563-8E48-326ACF87C706</gtr:id><gtr:name>University Hospital of Wales</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:department>Research and Commercial Division</gtr:department><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD1F1403-9928-4563-8E48-326ACF87C706"><gtr:id>DD1F1403-9928-4563-8E48-326ACF87C706</gtr:id><gtr:name>University Hospital of Wales</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EBF62057-C51F-47BB-9B80-D3AA4A7ACD29"><gtr:id>EBF62057-C51F-47BB-9B80-D3AA4A7ACD29</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>B.</gtr:otherNames><gtr:surname>Dunnett</gtr:surname><gtr:orcidId>0000-0003-1826-1578</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/53E7EF11-FCED-4F39-89E8-38E69990FC29"><gtr:id>53E7EF11-FCED-4F39-89E8-38E69990FC29</gtr:id><gtr:firstName>Anne Elizabeth</gtr:firstName><gtr:surname>Rosser</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800394"><gtr:id>F9EFEFDB-0385-4282-AD36-99C160EF52BF</gtr:id><gtr:title>Viability, specificity and yields of clinical grade primary and expanded human fetal cells for neural transplantation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800394</gtr:grantReference><gtr:abstractText>The MRC has sponsored a multicentre clinical trial on the safety and fesibility of fetal neural tissue transplantation in a severe progressive degenerative disease of the brain, Huntington s disease. However, this trial has been suspended after completion of the first 5 transplants because of the implementation of new EU regulations that require pharmaceutical grade handling of any cells or tissues used in patients. Although the UK trial had fully assessed the safety of the cells, we could not comply with the very stringent environmental control conditions required for accreditation. We have therefore undertaken a full rebuild of the laboratories to comply with the new regulations. In the present grant, we will undertake the detailed studies required to validate new laboratory procedures for cell preparation and expansion in cell culture and confirm the efficacy of the cells in animal models. This will allow us to complete the suspended HD trial, and to extend the multicentre UK cell transplant programme to trials in Parkinson s as well as Huntington s disease.</gtr:abstractText><gtr:technicalSummary>The MRC-sponsored multicentre UK pilot trial on the safety and fesibility of fetal neural tissue transplantation in Huntington s disease is currently suspended following introduction of the EU Cells and Tissue directive. We are just completing conversion of a small GMP laboratory in Cardiff University for handling of clinical-grade primary and short-term expanded fetal neural progenitor cells for application in neurodegenerative disease. This application is to undertake the translational studies required to validate cell preparation and expansion protocols under GMP, both to allow us to complete the suspended HD trial, and to define improved cell preparations for subsequent multicentre UK trials in both Parkinson s and Huntington s diseases.</gtr:technicalSummary><gtr:fund><gtr:end>2011-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>686594</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Wales</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>O&amp;amp;G/UHW</gtr:description><gtr:id>42F522C5-7D45-4121-8D7E-34FA4C2CAD4A</gtr:id><gtr:impact>Recent major development in identification of mTOPs as new source of fetal tissues for research and therapy.</gtr:impact><gtr:outcomeId>13C968B88C7-1</gtr:outcomeId><gtr:partnerContribution>Ongoing collaboration with O&amp;amp;G fundamental to our consented ethical collection of human fetal tissues.</gtr:partnerContribution><gtr:piContribution>Ongoing collaboration with O&amp;amp;G fundamental to our consented ethical collection of human fetal tissues. Processing, preparation, and validation in vitro and in vivo of cell and tissue viability and potential for functional repair</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>John van Geest Centre for Brain Repair</gtr:department><gtr:description>EU FP7 Transeuro</gtr:description><gtr:id>6835B0B8-2DE8-41BE-A471-2451129BAD2A</gtr:id><gtr:impact>collaborative clinical trial</gtr:impact><gtr:outcomeId>cFokQbRcp8W-1</gtr:outcomeId><gtr:partnerContribution>collabortive experiments</gtr:partnerContribution><gtr:piContribution>supply of cells and protocols</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>10-15 presentations to HDA and PDS patient groups</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>9387F605-EFC8-4127-826F-44EBA0F7FD92</gtr:id><gtr:impact>10-15 presentations to HDA and PDS patient groups. I present regular medical and lay seminars around the country and internationally. I am afraid I am unable to list all the individual presentations.

academic, medical and patient contacts</gtr:impact><gtr:outcomeId>014EB56EA63</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>10-15 presentations to HDA and PDS patient groups.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>C115700A-93DC-4AE0-BA7B-D2DB8D582A97</gtr:id><gtr:impact>I present regular medical and lay seminars around the country and internationally. I am afraid I am unable to list all the individual presentations.

various</gtr:impact><gtr:outcomeId>23C57C21F20</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>results included in multiple public and academic lectures and seminars</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>276C183E-F6AD-4882-B1E4-B98F6628B7C1</gtr:id><gtr:impact>results included in multiple public and academic lectures and seminars

various</gtr:impact><gtr:outcomeId>2B80FAEA334</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>10-15 presentations to HDA and PDS patient groups.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>4DB23CCC-400D-4D90-A3F1-972C8E80CF26</gtr:id><gtr:impact>10-15 presentations to HDA and PDS patient groups. I present regular medical and lay seminars around the country and internationally. I am afraid I am unable to list all the individual presentations.

various</gtr:impact><gtr:outcomeId>4E533867798</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>10-15 presentations to HDA and PDS patient groups.</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>8E86374C-402E-467F-823E-F6E22BED82D5</gtr:id><gtr:impact>I present regular medical and lay seminars around the country and internationally. I am afraid I am unable to list all the individual presentations.

various</gtr:impact><gtr:outcomeId>757CF680ED8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>results included in multiple public and academic lectures and seminars</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>70E73F6B-ADBE-4075-AF83-97F7765931D9</gtr:id><gtr:impact>results included in multiple public and academic lectures and seminars

various</gtr:impact><gtr:outcomeId>A1F186CD181</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC Stem Cells</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>0926941E-FDCF-472E-B8BC-5695EB82A393</gtr:id><gtr:impact>I participate in the MRC UK Stem Cell Bank users group and contribute regularly to the policy discussions at head office on stem cell strategy and funding.</gtr:impact><gtr:outcomeId>7E9135DE564</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC stem cell</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>029E0EA1-A24D-40AC-8EC3-A16F64D0FA5D</gtr:id><gtr:impact>I participate in the MRC Stem Cell Bank User's group and participate regularly in MRC stem cell policy and funding strategy meetings at Head Office.</gtr:impact><gtr:outcomeId>F2D8A6F3BAF</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>regular citations in clinical reviews and publications</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>4370633F-15DC-4BC3-B5DE-98007C0170A9</gtr:id><gtr:impact>influence on development of NECTAR and ASNTR guidelines</gtr:impact><gtr:outcomeId>35DB9587696</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>CD0451DC-042A-4C2A-BF48-1EF5829E345A</gtr:id><gtr:impact>Targetted direction, policy and funding of UK stem cell research .</gtr:impact><gtr:outcomeId>5AA8378353A</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>UKSCB SC</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>E497A6ED-7A0F-4EE7-9884-821BF93173F1</gtr:id><gtr:impact>Appointed as academic member of the UK Stem Cell Bank Steering Committee</gtr:impact><gtr:outcomeId>fsWdJiTu78j</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC stem cells</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>9BB3B52C-BA1C-40F0-B09C-259FC68ED09B</gtr:id><gtr:impact>I participate in the MRC Stem Cell Bank User's group and participate regularly in MRC stem cell policy and funding strategy meetings at Head Office.</gtr:impact><gtr:outcomeId>046F92CC2E5</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>GTAC</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>286776FD-FAFD-4481-85C8-6209B50B0422</gtr:id><gtr:impact>member of GTAC committee reviewing applications and developing policy on stem cell and gene therapy trials in the UK</gtr:impact><gtr:outcomeId>80395A16996</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>GTAC</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>EEBE152C-454E-43F1-93E3-752ABA114881</gtr:id><gtr:impact>development of national ethical and regulatory guidelines</gtr:impact><gtr:outcomeId>2F7263565E5</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citations in clinical guidelines and reviews</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>36BEB30A-C350-4C95-A642-89FEBD5EA363</gtr:id><gtr:impact>we contribute to ongoing debate and updating of guidelines on ethical sourcing of human fetal tissues for research and clinical cell transplantation.</gtr:impact><gtr:outcomeId>0A7A1912D35</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>GMP processing of human cells
Trials ready to commence.
Funding expired and all initial applications rejected</gtr:description><gtr:id>C134D90A-38FA-4F23-B6B5-CF10DDF4F2C5</gtr:id><gtr:impact>no impact as stalled due to funding hiatus</gtr:impact><gtr:outcomeId>YwG8Hb2STeK</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>GMP grade human cells</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Validation of alternative protocols for consented collection of human fetal tissue</gtr:description><gtr:id>B4CE95CF-DB61-4BA4-9F1A-463F1B5B6523</gtr:id><gtr:impact>Resolves the outstanding block on limited tissue availability to allow multiple international research and clinical trials to resume.</gtr:impact><gtr:outcomeId>CD8A8553171</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>mTOPs</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>human fetal cells collected via licenced and approved tissue bank. we use neural tissues, other tissues available for research use to others subject to appropriate ethical consents</gtr:description><gtr:id>F8DAFAA3-1240-43CB-91DA-B99ADFD1989B</gtr:id><gtr:impact>eyes, kidney, liver, brain all used sporadically by others</gtr:impact><gtr:outcomeId>GNwn7fSF2wa</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Human embryonic cells</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>11D584B3-6ECB-472E-A111-2A5E60FEDA8D</gtr:id><gtr:title>Technical factors that influence neural transplant safety in Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d4d61f1989497f58e7e2aa47dda4712"><gtr:id>5d4d61f1989497f58e7e2aa47dda4712</gtr:id><gtr:otherNames>Freeman TB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0014-4886</gtr:issn><gtr:outcomeId>n9FH1w68KyM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99E3B1B2-5DD6-4F57-8359-649C73C98FDE</gtr:id><gtr:title>Medical terminations of pregnancy: a viable source of tissue for cell replacement therapy for neurodegenerative disorders.</gtr:title><gtr:parentPublicationTitle>Cell transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9dd96bb733c0726221ef84de4144119"><gtr:id>f9dd96bb733c0726221ef84de4144119</gtr:id><gtr:otherNames>Kelly CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0963-6897</gtr:issn><gtr:outcomeId>UmN7KDJtpSC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78560EAD-A691-4B21-8151-676FD9320E42</gtr:id><gtr:title>Repair of the CNS using endogenous and transplanted neural stem cells.</gtr:title><gtr:parentPublicationTitle>Current topics in behavioral neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/361fffb92b7a55bf0faec7a2216c7339"><gtr:id>361fffb92b7a55bf0faec7a2216c7339</gtr:id><gtr:otherNames>Trueman RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1866-3370</gtr:issn><gtr:outcomeId>pm_14019_29_22907556</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71E37322-5DB7-4D78-8D14-7841DC635F18</gtr:id><gtr:title>Neurorehabilitation with neural transplantation.</gtr:title><gtr:parentPublicationTitle>Neurorehabilitation and neural repair</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e3e2a90e1af6b04e560146685d71bbe"><gtr:id>6e3e2a90e1af6b04e560146685d71bbe</gtr:id><gtr:otherNames>D?br?ssy M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1545-9683</gtr:issn><gtr:outcomeId>pm_14019_29_20647502</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE67D1A7-2532-41EB-B93C-98B84E75ACBA</gtr:id><gtr:title>Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9697b4cede3cd59594423f38cd663145"><gtr:id>9697b4cede3cd59594423f38cd663145</gtr:id><gtr:otherNames>Orth M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_14019_29_21097549</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF4C1E87-CF4A-46F5-8388-3C5EDE47469D</gtr:id><gtr:title>Medium spiny neurons for transplantation in Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9dd96bb733c0726221ef84de4144119"><gtr:id>f9dd96bb733c0726221ef84de4144119</gtr:id><gtr:otherNames>Kelly CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>34BE1103642</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3291D5B-DD3D-4546-9CEC-A431E5329A0C</gtr:id><gtr:title>Cell-based treatments for huntington's disease.</gtr:title><gtr:parentPublicationTitle>International review of neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2edda089a98ce18159ce9576c85efbc2"><gtr:id>2edda089a98ce18159ce9576c85efbc2</gtr:id><gtr:otherNames>Dunnett SB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0074-7742</gtr:issn><gtr:outcomeId>pm_14019_29_21907097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A08A31AD-5BD4-4375-A831-BF5175731193</gtr:id><gtr:title>Neural grafting in Parkinson's disease unraveling the mechanisms underlying graft-induced dyskinesia.</gtr:title><gtr:parentPublicationTitle>Progress in brain research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbe135285b83ddc9d62cae2090f558d2"><gtr:id>cbe135285b83ddc9d62cae2090f558d2</gtr:id><gtr:otherNames>Lane EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0079-6123</gtr:issn><gtr:outcomeId>pm_14019_29_20887881</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D68C4FE1-C432-41E4-A472-AB1574AC02CD</gtr:id><gtr:title>Discrepancies in reporting the CAG repeat lengths for Huntington's disease.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a05f31ac6f38e827c4cca4d5f2e577d5"><gtr:id>a05f31ac6f38e827c4cca4d5f2e577d5</gtr:id><gtr:otherNames>Quarrell OW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>pm_14019_29_21811303</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90E921BE-9874-4F2B-BFD0-5F1DDCC8158E</gtr:id><gtr:title>Clinical translation of cell transplantation in the brain.</gtr:title><gtr:parentPublicationTitle>Current opinion in organ transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2edda089a98ce18159ce9576c85efbc2"><gtr:id>2edda089a98ce18159ce9576c85efbc2</gtr:id><gtr:otherNames>Dunnett SB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1087-2418</gtr:issn><gtr:outcomeId>NhvuxCGE54a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74EE44A8-F1A7-47F0-B03F-29A863FF59D1</gtr:id><gtr:title>Survival and functional restoration of human fetal ventral mesencephalon following transplantation in a rat model of Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Cell transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82d0323ecbfb1ed5d0c6018cc116373a"><gtr:id>82d0323ecbfb1ed5d0c6018cc116373a</gtr:id><gtr:otherNames>Rath A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0963-6897</gtr:issn><gtr:outcomeId>pm_14019_29_22963760</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3BE11E0-A7D0-4716-8D92-9BEC9DEAC806</gtr:id><gtr:title>Long-term expansion of human foetal neural progenitors leads to reduced graft viability in the neonatal rat brain.</gtr:title><gtr:parentPublicationTitle>Experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4deb31f760faf1ed0b3297504f95ebb"><gtr:id>e4deb31f760faf1ed0b3297504f95ebb</gtr:id><gtr:otherNames>Zietlow R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0014-4886</gtr:issn><gtr:outcomeId>pm_15939_29_22475737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6154380-2982-4E59-A537-FA91FC913697</gtr:id><gtr:title>Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY.</gtr:title><gtr:parentPublicationTitle>PLoS currents</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9697b4cede3cd59594423f38cd663145"><gtr:id>9697b4cede3cd59594423f38cd663145</gtr:id><gtr:otherNames>Orth M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>2157-3999</gtr:issn><gtr:outcomeId>pm_14019_29_20890398</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800394</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>